← Back to home

HIGH RISK BIOCHEMICAL RECURRENCE OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Clinical trials for HIGH RISK BIOCHEMICAL RECURRENCE OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER explained in plain language.

Never miss a new study

Get alerted when new HIGH RISK BIOCHEMICAL RECURRENCE OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER trials appear

Sign up with your email to follow new studies for HIGH RISK BIOCHEMICAL RECURRENCE OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug tested to stop prostate Cancer's return

Disease control Ongoing

This early-stage study is testing the safety and initial effectiveness of an experimental drug called xaluritamig. It involves about 50 men whose prostate cancer has started to return (shown by rising PSA levels) but hasn't spread to other body parts. The main goal is to see if t…

Matched conditions: HIGH RISK BIOCHEMICAL RECURRENCE OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

HIGH RISK BIOCHEMICAL RECURRENCE OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Get alerted when new HIGH RISK BIOCHEMICAL RECURRENCE OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER trials appear

New drug tested to stop prostate Cancer's return